The Chinese patients with chronic hepatitis C have a different genetic background, which had been demonstrated to significantly influence their responses to pegylated interferon and ribavirin. In this study, Chinese patients with Hepatitis C Virus genotype 1, 2/3, 6 infection were treated with pegylated interferon and ribavirin. Their response was compared amongst different genotypes.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
535
patients receive a dose of 180 µg of PEGASYS once a week for 48 weeks
patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 48 weeks
patients receive a dose of 180 µg of PEGASYS once a week for 24 weeks
The Eighth People's Hospital of Guangzhou
Guangzhou, Guangdong, China
The Third Affliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China
Zhongshan second people's hospital
Zhongshan, Guangdong, China
Sustained virological response (SVR)
Undetectable HCVRNA in serum(\<15IU/ml) 24 weeks after the end of treatment
Time frame: 24 weeks after the end of treatment
Change in health related quality as measured by short form 36 (SF-36) from baseline to 24 weeks after the end of treatment
Time frame: 24 weeks after the end of treatment
Sick leave in patients treated for 24 or 48 weeks treatment
Time frame: 48 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 24 weeks